Emibetuzumab ELISA Kit

Catalog No.

KDC34201

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human MET has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Emibetuzumab in the sample competitively binds to the pre-coated protein with biotin-labeled Emibetuzumab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Emibetuzumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Emibetuzumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

125 - 8,000 ng/mL

Sensitivity

89.12 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	2982.0	890.5	304.9	3404.9	958.9	274.7
Standard deviation	510.2	69.5	41.1	553.2	76.6	32.6
CV (%)	17.1	7.8	13.5	16.2	8.0	11.9

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

LA480, LY-2875358, CAS: 1365287-97-3

Background

Emibetuzumab (as known as LY2875358) is a humanized immunoglobulin G4 monoclonal bivalent anti-MET antibody that blocks MET signaling. This drug was developed by Eli Lilly & Company and has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. In preclinical models, emibetuzumab inhibited growth of tumors that are dependent on MET, including tumors that exhibit HGF-dependent and HGF-independent biology. Administration of a single dose of emibetuzumab resulted in continuous reduction of MET protein expression for 14 days in mouse xenografts. Emibetuzumab demonstrated dose-dependent, single-agent activity in various MET-expressing tumor models, and additive effects were observed in combination with erlotinib for reducing tumor volume in lung cancer mouse xenograft models. In Phase 1 dose escalation studies, emibetuzumab monotherapy was well tolerated in patients with advanced solid tumors, including gastric cancer, with no dose-limiting toxicities.

Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions., PMID:39449330

Evaluating the chaos game representation of proteins for applications in machine learning models: prediction of antibody affinity and specificity as a case study., PMID:37968495

Position-Specific Enrichment Ratio Matrix scores predict antibody variant properties from deep sequencing data., PMID:37503142

Position-Specific Enrichment Ratio Matrix scores predict antibody variant properties from deep sequencing data., PMID:37478351

Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space., PMID:35778381

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib., PMID:35400584

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer., PMID:33638808

MARCH Proteins Mediate Responses to Antitumor Antibodies., PMID:33077644

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer., PMID:32575417

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients., PMID:31622732

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer., PMID:31142504

Targeting the C-MET/HGF Signaling Pathway in Pancreatic Ductal Adenocarcinoma., PMID:30636579

Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015., PMID:29545332

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping., PMID:29188469

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer., PMID:29071414

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors., PMID:28679766

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer., PMID:27803065

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies., PMID:27422720

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth., PMID:25231402

Document Download

Emibetuzumab ELISA Kit.pdf